吉西他滨联合卡培他滨治疗晚期三阴性乳腺癌的临床疗效与安全性。
Clinical effectiveness and safety of gemcitabine plus capecitabine in the treatment of advanced triple-negative breast cancer.
作者信息
Wang Ya, Zhu Yulan
机构信息
Nanjing Medical University Nanjing 213003, Jiangsu, China.
出版信息
Am J Transl Res. 2024 May 15;16(5):1945-1952. doi: 10.62347/QOWN3646. eCollection 2024.
PURPOSE
To determine the clinical effectiveness and safety of Gemcitabine (GEM) plus Capecitabine (CAP) for advanced triple-negative breast cancer (aTNBC).
METHODS
Eighty aTNBC patients treated in Affiliated Hospital of Nanjing Medical University between June 2020 and June 2022 were retrospectively included and divided into an observation group (Obs; 42 cases treated with GEM + CAP) and a control group (Con; 38 cases treated with docetaxel + CAP) according to different chemotherapy regimens. The clinical effectiveness and the serum levels of tumor markers and inflammatory factors pre- and post-treatment were detected for comparative analyses. In addition, the two groups were compared in terms of side effects, 1-year survival, and quality of life after 1 month of treatment. Cox regression was performed to identify the independent risk factors affecting patient prognosis.
RESULTS
Higher clinical effectiveness was observed in the Obs group compared to the Con (P < 0.05). The pre-treatment TPS, CA153, TNF-α, and IL-6 levels were comparable between groups (all P > 0.05); however, better post-treatment TPS, CA153, and inflammatory factors were observed in the Obs group compared to the Con (all P < 0.05). The Obs group also showed markedly lower drug-induced toxicities than the Con group, with higher 1-year survival and better quality-of-life after 1 month of treatment (all P < 0.05). According to multivariate analysis, clinical stage and lymph node metastasis were independent risk factors for poor prognosis, and GEM + CAP chemotherapy was a protective prognostic factor.
CONCLUSIONS
GEM + CAP is effective in treating aTNBC and provides clinical benefit for patients, with fewer side effects and good patient tolerance.
目的
确定吉西他滨（GEM）联合卡培他滨（CAP）治疗晚期三阴性乳腺癌（aTNBC）的临床疗效和安全性。
方法
回顾性纳入2020年6月至2022年6月在南京医科大学附属医院接受治疗的80例aTNBC患者，根据不同化疗方案分为观察组（Obs；42例接受GEM + CAP治疗）和对照组（Con；38例接受多西他赛 + CAP治疗）。检测治疗前后的临床疗效、肿瘤标志物和炎症因子血清水平进行比较分析。此外，比较两组的副作用、1年生存率和治疗1个月后的生活质量。进行Cox回归分析以确定影响患者预后的独立危险因素。
结果
与Con组相比，Obs组观察到更高的临床疗效（P < 0.05）。两组治疗前的TPS、CA153、TNF-α和IL-6水平相当（均P > 0.05）；然而，与Con组相比，Obs组治疗后的TPS、CA153和炎症因子水平更好（均P < 0.05）。Obs组的药物诱导毒性也明显低于Con组，1年生存率更高，治疗1个月后的生活质量更好（均P < 0.05）。多因素分析显示，临床分期和淋巴结转移是预后不良的独立危险因素，GEM + CAP化疗是预后的保护因素。
结论
GEM + CAP治疗aTNBC有效，为患者提供临床益处，副作用较少，患者耐受性良好。
Zotero 插件